XML 53 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1

Revenue (Tables)

12 Months Ended

Dec. 31, 2023

Revenue

Schedule of Net product revenue in United States, and Company's net revenue

​

​	​	​	​	​	​	​	​	​	​
​	​	Year Ended December 31,
(in thousands)		2023		​	2022		​	2021
Products	​	​	​	​	​	​	​	​	​
UDENYCA	​	$	127,064	​	$	203,814	​	$	326,509
CIMERLI	​	​	125,388	​	​	6,946	​	​	—
YUSIMRY	​	​	3,574	​	​	—	​	​	—
LOQTORZI	​	​	554	​	​	—	​	​	—
Total net product revenue	​	​	256,580	​	​	210,760	​	​	326,509
Other	​		664	​		282	​		42
Total net revenue	​	$	257,244	​	$	211,042	​	$	326,551

Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues

​

​	​	​	​	​	​	​	​	​
​	Year Ended December 31,
​	2023	​	​	2022		​	2021
McKesson Corporation	40	%	​	38	%	​	39	%
Cencora (previously known as AmeriSource-Bergen Corporation)	43	%	​	44	%	​	39	%
Cardinal Health, Inc.	15	%	​	17	%	​	20	%

​

Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks

​

​

Other Fees,

​

​

​

​

and Discounts

​

​

​

​

Co-pay

​

​

​

​

​

for Prompt

​

​

​

​

Assistance

​

​

​

(in thousands)

​

Payment

​

Rebates

​

and Returns

​

Total

Balances at December 31, 2020

​

$

40,580

​

$

54,058

​

$

28,760

​

$

123,398

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

470,791

​

​

113,705

​

​

94,703

​

​

679,199

Prior period - increase (decrease)

​

​

(2,876)

​

​

(4,976)

​

​

(3,555)

​

​

(11,407)

Payments and customer credits issued

​

(478,830)

​

(108,783)

​

(93,854)

​

(681,467)

Balances at December 31, 2021

​

​

29,665

​

​

54,004

​

​

26,054

​

​

109,723

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

​

436,865

​

​

68,399

​

​

73,435

​

​

578,699

Prior period - increase (decrease)

​

​

(2,090)

​

​

(1,050)

​

​

32

​

​

(3,108)

Payments and customer credits issued

​

​

(421,763)

​

​

(82,640)

​

​

(80,408)

​

​

(584,811)

Balances at December 31, 2022

​

​

42,677

​

​

38,713

​

​

19,113

​

​

100,503

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

​

590,772

​

​

143,370

​

​

110,183

​

​

844,325

Prior period - increase (decrease)

​

​

(1,361)

​

​

1,424

​

​

3,744

​

​

3,807

Payments and customer credits issued

​

(558,135)

​

​

(62,370)

​

​

(83,245)

​

​

(703,750)

Balances at December 31, 2023

​

$

73,953

​

$

121,137

​

$

49,795

​

$

244,885

​

X

- Definition

Schedule of product sales discounts and allowances.

+ References

No definition available.

+ Details

Name:	chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock
Namespace Prefix:	chrs_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration